Liquid biopsy in lung cancer management

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Liquid biopsy is a minimally invasive alternative to traditional tissue biopsy for cancer management.
• It enables detection of mutations, monitoring of tumor mutational burden, and prediction of therapy response.
• Lung cancer, a leading cause of cancer death, could significantly benefit from improved diagnostic and monitoring tools.

Purpose of the Study:

• To highlight the potential of liquid biopsy as a source of cancer biomarkers.
• To explore the application of liquid biopsy in lung cancer management.
• To discuss the types of biomarkers detectable via liquid biopsy and their clinical significance.

Main Methods:

• Analysis of circulating tumor cells (CTCs) and cell-free nucleic acids (cfNAs) including cell-free ribonucleic acid (cfRNA) and cell-free deoxyribonucleic acid (cfDNA).
• Detection of exosomes and tumor-educated platelets (TEPs) in peripheral blood samples.
• Utilizing liquid biopsy for real-time monitoring of treatment response and tumor profiling.

Main Results:

• Liquid biopsy provides a valuable source of cancer biomarkers, improving patient management.
• Biomarkers like CTCs, cfNAs, exosomes, and TEPs shed from tumors into circulation.
• The detection and analysis of these biomarkers enhance the understanding of lung cancer.

Conclusions:

• Liquid biopsy holds significant potential for improving lung cancer diagnosis, monitoring, and treatment.
• Despite limitations such as low biomarker concentration, advancements in technology are expected to overcome these challenges.
• Further development of liquid biopsy methods will enhance its clinical utility in oncology.